摘要
采用酶联免疫吸附试验、流式细胞术、放射配体结合试验及蛋白质印迹等方法,首次证实了人T细胞系Jurkat表达特异性C1q受体,并对其特性进行了分析Jurkat可为C1q或抗人C1q受体抗体112识别,其对异硫氰酸荧光黄标记C1q的结合能被未标记C1q所抑制.在生理离子强度和温度条件下,Jurkat与125I-C1q的结合呈持异、剂量依赖、可饱和及可逆性,每个细胞C1q结合位点数为1.1×106,对C1q的Ka值为1.5×107mol-1,Hill系数为0.9643.JurkatC1q受体识别C1q的胶原样区.
The C1q receptor (C1qR) on the human T lymphocyte line Jurkat cells was demonstrated and characterized. Cell-ELISA showed that Jurkat cells are able to bind exogenous C1q and recognized by the anti-C1qRantibody 112. FCM analysis indicated that the binding of FITC-C1q to Jurkat cells is blocked by an excess of unlabelled C1q.Quantitative binding studies with monomeric 125 I-C1q showed a specific, dose-dependent,saturable and reversible binding involving specific membrane receptors on Jurkat cells, Goldstein analysis and Hill plot of C1q binding showed 1. 1 × 106 binding sites per cell with an average affinity of 1. 5 ×107 mol-1and a Hill number of 0.9643 at normal ionic strength (I = 0. 15 ) and temperature (37℃).The experiment with the anti-C1q monoclonal antibody A4, which recognizes the collagen-like region (CLR) of C1q, established that it is via its CLR that C1q binds to Jurkat cell receptors.Western blotting with the anti-C1qR antibody 112 revealed that the C1qR on Jurkat cells is a membrane protein of 70 ku.
出处
《生物化学与生物物理进展》
SCIE
CAS
CSCD
北大核心
1996年第2期164-168,共5页
Progress In Biochemistry and Biophysics
基金
全军"八五"医药卫生科研基金